Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 5/20 | 0.38 |
| ▸ | CCNC | P24863 | 3/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953317 | 1.00 | NOTUM (0.44) | NOTUMERCC1ERCC4CA1CA2 | |
| SCHEMBL21172 | 0.86 | TRPA1 (0.42) | NOTUMCA1CA2PDE1CCDK8 | |
| SCHEMBL29722623 | 0.86 | TRPA1 (0.42) | NOTUMCA1CA2PDE1CCDK8 | |
| SCHEMBL17673592 | 0.77 | PDE1C (0.38) | NOTUMERCC1ERCC4PDE1CCDK8 | |
| SCHEMBL31754002 | 0.76 | HTR2A (0.62) | NOTUMERCC1ERCC4PDE1CHTR2A | |
| SCHEMBL15730607 | 0.76 | HTR2A (0.62) | NOTUMERCC1ERCC4PDE1CHTR2A | |
| SCHEMBL30444577 | 0.75 | NOTUM (0.42) | NOTUMERCC1ERCC4PDE1CHTR2A | |
| SCHEMBL30401124 | 0.75 | MGLL (0.39) | CA1CA2ENPP2CYP11B2 | |
| SCHEMBL29906309 | 0.75 | CA1 (0.38) | CA1CA2PDE1CCDK8CCNC | |
| SCHEMBL24873777 | 0.74 | HTR2A (0.39) | CA1CA2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612387-B2 | RAS inhibitors and methods of using the same | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2026-04-28 | — | — | US | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| EP-4543446-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119768169-A | Substituted fused bicyclic compounds and related methods of treatment | 阿尔克姆斯有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| EP-2619201-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130029949-A1 | Substituted Quinolines and Their Use As Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014060-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011101640-A1 | FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-08-25 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | NOTUM 556/4885ERCC1 3849/4885ERCC4 4062/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | NOTUM 3519/4885ERCC1 2920/4885ERCC4 1788/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | NOTUM 2747/4885ERCC1 1137/4885ERCC4 695/4885 |
| US-12612387-B2 | RAS inhibitors and methods of using the same | KRAS, NRAS, HRAS | NOTUM 4400/4885ERCC1 798/4885ERCC4 1450/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | NOTUM 3637/4885ERCC1 1162/4885ERCC4 2127/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | NOTUM 517/4885ERCC1 3940/4885ERCC4 3290/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | NOTUM 2689/4885ERCC1 3954/4885ERCC4 3895/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | NOTUM 4046/4885ERCC1 2069/4885ERCC4 3181/4885 |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NOTUM 2400/4885ERCC1 3256/4885ERCC4 1954/4885 |
| US-20130029949-A1 | Substituted Quinolines and Their Use As Medicaments | QARS1, RECQL, CYP3A7 | NOTUM 3373/4885ERCC1 2163/4885ERCC4 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.